St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
Non-Hodgkin Lymphoma Treatment
Also called: Non-Hodgkin’s lymphoma, NHL
Non-Hodgkin lymphoma is a form of cancer that affects the lymphatic system, part of the body’s immune system. It is a group name for all lymphomas except Hodgkin lymphoma.
White blood cells called lymphocytes help to fight infection in healthy people. In people with non-Hodgkin lymphoma, these lymphocytes develop an error and begin to grow out of control.
The cancer can begin anywhere in the lymphatic system (lymph nodes, bone marrow, spleen, or tonsils for example) and can spread to the other parts of the lymphatic system or other places in the body like the liver, lungs, or bones.
The survival rate for non-Hodgkin lymphoma in children in the United States is about 90% (9 in 10).
Primary mediastinal B-cell lymphoma (PMBCL) is a form of non-Hodgkin lymphoma that begins in B cells located in the area between the lungs, known as the mediastinum.
Learn more about non-Hodgkin lymphoma and primary mediastinal B-cell lymphoma on the Together by St. Jude™ online resource.
Carol and Katie (mom and daughter) share their journey through cancer, highlighting the importance of communication, self-advocacy, and listening during tough times.
Non-Hodgkin lymphoma treatment
Chemotherapy (“chemo”) is the most common treatment for non-Hodgkin lymphoma.
Treatment methods may include:
Non-Hodgkin lymphoma clinical trials
St. Jude offers clinical trials and cancer research studies for children, teens, and young adults for non-Hodgkin lymphoma. Learn more about clinical research at St. Jude.
Recruiting
Study goal:
The main purpose of this study is to find out how well the medicine tegavivint works to help children, teens, and young adults with certain recurrent or refractory solid tumors.
Age:
12 months to 30 years
Recruiting
Study goal:
To find out whether a child’s leukemia or lymphoma is low-risk, standard-risk, or high-risk. The risk category will determine the treatment the child will receive.
Age:
1-18 years
Recruiting
Study goal:
To compare the effects of adding inotuzumab and blinatumomab to standard chemotherapy during treatment for newly diagnosed ALL and LLy; to learn whether the length of time that inotuzumab stays in the body affects treatment success or side effects; to learn more about the biological and genetic or genomic traits that predict treatment success and toxicity in children.
Age:
1-18 years
Recruiting
Study goal:
To determine if cardiac autonomic dysfunction can be diagnosed remotely in leukemia and lymphoma survivors
Age:
18 years or older
St. Jude provides the highest quality of care for patients with non-Hodgkin lymphoma:
Scientists work with doctors to learn more about how non-Hodgkin lymphoma develops. For example, researchers at St. Jude found that inherited changes (mutations) in the BRCA2 gene were linked with an increased risk of non-Hodgkin lymphoma in children and teens. Our staff has also led the way to understanding which long-term side-effects patients treated with current therapies are potentially at risk for.
St. Jude offers a dedicated team of specialists to meet the needs of children with cancer, including:
- Surgeons, doctors, and nurses who treat this cancer
- Doctors who specialize in radiation therapy and pathology (making a diagnosis by looking at tumor tissue under the microscope)
- Experts in radiology and nuclear medicine
- Genetic counselors
- Clinical dietitians
- Child life specialists
- Psychologists
- Researchers and scientists
More reasons to choose St. Jude for care include:
We are consistently ranked among the best childhood cancer centers in the nation by US News & World Report.
At St. Jude, we have created an environment where children can be children and families can be together.
We lead more clinical trials for childhood cancer than any other hospital in the U.S.
St. Jude is the only National Cancer Institute–designated Comprehensive Cancer Center just for children. A Comprehensive Cancer Center meets rigorous standards for research that develops new and better approaches to prevent, diagnose, and treat cancer.
The nurse-to-patient ratio at St. Jude is about 1:3 in hematology and oncology and 1:1 in the Intensive Care Unit.
Patients may be able to get expert, compassionate care and treatment closer to their homes through the St. Jude Affiliate Program.
Seeking treatment at St. Jude
Patients accepted to St. Jude must have a disease we treat and must be referred by a physician or other qualified medical professional. We accept most patients based on their ability to enroll in an open clinical trial.
Contact the Physician / Patient Referral Office
Call: 1-888-226-4343 (toll-free) or 901-595-4055 (local) | Fax: 901-595-4011 | Email: referralinfo@stjude.org | 24-hour pager: 1-800-349-4334